靶向卵巢癌中的AXL信号通路。
Targeting the AXL signaling pathway in ovarian cancer.
作者信息
Huang Ruby Yun-Ju, Antony Jane, Tan Tuan Zea, Tan David Shao-Peng
机构信息
Department of Obstetrics & Gynaecology, National University Hospital of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Cancer Science Institute of Singapore, National University of Singapore, Singapore; NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
出版信息
Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.
Abstract
In a recent publication in , we showed that a Mes molecular subtype of epithelial ovarian cancer (EOC) harboring epithelial-mesenchymal transition (EMT) features has a unique signaling network downstream of the GAS6/AXL pathway. Our finding leads to a potential strategy for treating the Mes subtype of EOC by targeting AXL.
摘要
在最近发表于《 》的一篇论文中，我们表明，具有上皮-间质转化（EMT）特征的上皮性卵巢癌（EOC）的Mes分子亚型在GAS6/AXL通路下游具有独特的信号网络。我们的发现为通过靶向AXL治疗EOC的Mes亚型提供了一种潜在策略。
相似文献
1
Targeting the AXL signaling pathway in ovarian cancer.
Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.
2
Differential Expression Pattern of Epithelial Mesenchymal Transition Gens: AXL, GAS6, Claudin-1, and Cofilin-1, in Different Stages of Epithelial Ovarian Cancer.
Iran J Public Health. 2019 Sep;48(9):1723-1731.
3
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
BMC Cancer. 2019 Jun 24;19(1):618. doi: 10.1186/s12885-019-5824-9.
4
Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.
Exp Ther Med. 2017 Jul;14(1):785-790. doi: 10.3892/etm.2017.4532. Epub 2017 Jun 1.
5
RhoA-Dependent HGF and c-Met Mediate Gas6-Induced Inhibition of Epithelial-Mesenchymal Transition, Migration, and Invasion of Lung Alveolar Epithelial Cells.
Biomolecules. 2019 Oct 4;9(10):565. doi: 10.3390/biom9100565.
6
LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.
Biomed Pharmacother. 2017 Dec;96:1216-1221. doi: 10.1016/j.biopha.2017.11.096. Epub 2017 Nov 26.
7
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
8
AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Lung Cancer (Auckl). 2015 Apr 30;6:27-34. doi: 10.2147/LCTT.S60438. eCollection 2015.
9
TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Endocr Relat Cancer. 2016 Mar;23(3):147-59. doi: 10.1530/ERC-15-0383. Epub 2015 Dec 8.
10
TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Gynecol Oncol. 2017 Nov;147(2):408-417. doi: 10.1016/j.ygyno.2017.08.010. Epub 2017 Aug 26.
引用本文的文献
1
Regulation of mA (N-Methyladenosine) methylation modifiers in solid cancers.
Funct Integr Genomics. 2024 Oct 23;24(6):193. doi: 10.1007/s10142-024-01467-z.
2
Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.
Cells Tissues Organs. 2022;211(2):222-237. doi: 10.1159/000513039. Epub 2021 Mar 29.
3
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Cancer Gene Ther. 2021 Feb;28(1-2):18-26. doi: 10.1038/s41417-020-0187-6. Epub 2020 Jun 29.
4
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.
J Clin Med. 2019 Mar 8;8(3):330. doi: 10.3390/jcm8030330.
5
The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview.
Cells. 2018 Oct 12;7(10):166. doi: 10.3390/cells7100166.
6
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201846492. Epub 2018 Jul 2.
7
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201745670. Epub 2018 Jun 15.
本文引用的文献
1
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
2
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
Mol Cancer Res. 2017 Jan;15(1):45-58. doi: 10.1158/1541-7786.MCR-16-0157. Epub 2016 Sep 26.
3
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
4
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.
EMBO Mol Med. 2014 Oct;6(10):1279-93. doi: 10.15252/emmm.201404208.
5
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.
EMBO Mol Med. 2013 Jul;5(7):1051-66. doi: 10.1002/emmm.201201823. Epub 2013 May 13.
6
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.
7
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13.
8
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.
9
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28.
10
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Cancer Res. 2009 Aug 15;69(16):6381-6. doi: 10.1158/0008-5472.CAN-09-1178. Epub 2009 Aug 4.
Zotero 插件